- Home
- NTRA
NTRA
Natera Inc.
as of 04-06-2026 3:42pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 28.0B | IPO Year: | 2015 |
| Target Price: | $259.07 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | 0.65 |
| 52 Week Low/High: | $130.29 - $256.36 | Next Earning Date: | 05-07-2026 |
| Revenue: | $210,939,000 | Revenue Growth: | -2.83% |
| Revenue Growth (this year): | 18.16% | Revenue Growth (next year): | 20.00% |
| P/E Ratio: | -136.83 | Index: | N/A |
| Free Cash Flow: | 109.1M | FCF Growth: | +57.58% |
AI-Powered NTRA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Natera Inc. (NTRA)
EXECUTIVE CHAIRMAN
Avg Cost/Share
$194.28
Shares
50,000
Total Value
$9,813,883.47
Owned After
2,310,772
EXECUTIVE CHAIRMAN
Avg Cost/Share
$189.47
Shares
75,000
Total Value
$14,175,379.12
Owned After
2,310,772
EXECUTIVE CHAIRMAN
Avg Cost/Share
$191.08
Shares
75,000
Total Value
$14,294,119.06
Owned After
2,310,772
PRESIDENT, CLINICALDIAGNOSTICS
Avg Cost/Share
$204.13
Shares
915
Total Value
$186,781.42
Owned After
150,882
SEC Form 4
SEC. AND CHIEF LEGAL OFFICER
Avg Cost/Share
$204.13
Shares
1,745
Total Value
$356,211.56
Owned After
233,285
SEC Form 4
PRESIDENT, CHIEF BUS. OFFICER
Avg Cost/Share
$204.13
Shares
707
Total Value
$144,321.82
Owned After
189,199
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$204.13
Shares
785
Total Value
$160,244.17
Owned After
63,354
SEC Form 4
Director, Other
Avg Cost/Share
$204.13
Shares
127
Total Value
$25,924.85
Owned After
262,325
SEC Form 4
CEO AND PRESIDENT
Avg Cost/Share
$204.13
Shares
5,623
Total Value
$1,147,838.17
Owned After
156,607
SEC Form 4
SEC. AND CHIEF LEGAL OFFICER
Avg Cost/Share
$195.86
Shares
8,398
Total Value
$1,646,695.83
Owned After
233,285
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Mar 16, 2026 | Sell | $194.28 | 50,000 | $9,813,883.47 | 2,310,772 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Mar 13, 2026 | Sell | $189.47 | 75,000 | $14,175,379.12 | 2,310,772 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Mar 12, 2026 | Sell | $191.08 | 75,000 | $14,294,119.06 | 2,310,772 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Mar 10, 2026 | Sell | $204.13 | 915 | $186,781.42 | 150,882 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Mar 10, 2026 | Sell | $204.13 | 1,745 | $356,211.56 | 233,285 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Mar 10, 2026 | Sell | $204.13 | 707 | $144,321.82 | 189,199 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Mar 10, 2026 | Sell | $204.13 | 785 | $160,244.17 | 63,354 | |
| Sheena Jonathan | NTRA | Director, Other | Mar 10, 2026 | Sell | $204.13 | 127 | $25,924.85 | 262,325 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Mar 10, 2026 | Sell | $204.13 | 5,623 | $1,147,838.17 | 156,607 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Mar 6, 2026 | Sell | $195.86 | 8,398 | $1,646,695.83 | 233,285 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-4.75%
$205.84
Act: -4.27%
5D
-7.15%
$200.65
Act: -8.77%
20D
-5.65%
$203.90
false 0001604821
0001604821
2026-02-26 2026-02-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
Natera, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37478
01-0894487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
(Address of principal executive offices, including zip code)
(650) 980 9190
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTRA
Nasdaq Stock Market LLC (Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2026, Natera, Inc. issued a press release announcing the results for its fourth quarter and year ended December 31, 2025 and provided a related investor presentation. A copy of the press release and a copy of the investor presentation are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated February 26, 2026.
99.2
Investor Presentation.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Natera, Inc.
By: /s/ Michael Brophy
Michael Brophy
Chief Financial Officer (Principal Financial and Accounting Officer)
Dated: February 26, 2026
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-4.75%
$205.84
Act: -4.27%
5D
-7.15%
$200.65
Act: -8.77%
20D
-5.65%
$203.90
false 0001604821
0001604821
2026-01-11 2026-01-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2026
Natera, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37478
01-0894487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
(Address of principal executive offices, including zip code)
(650) 980-9190
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTRA
Nasdaq Stock Market LLC (Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On January 11, 2026, Natera, Inc. (the “Company”) issued a press release announcing preliminary financial results for its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated January 11, 2026.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Natera, Inc.
By: /s/ Michael Brophy
Michael Brophy
Chief Financial Officer (Principal Financial and Accounting Officer)
Dated: January 12, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
false 0001604821
0001604821
2025-11-06 2025-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
Natera, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-37478
01-0894487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
(Address of principal executive offices, including zip code)
(650) 980-9190
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTRA
Nasdaq Stock Market LLC (Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, Natera, Inc. issued a press release announcing the results for its third quarter ended September 30, 2025 and provided a related investor presentation. A copy of the press release and a copy of the investor presentation are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated November 6, 2025.
99.2
Investor Presentation.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Natera, Inc.
By: /s/ Michael Brophy
Michael Brophy
Chief Financial Officer (Principal Financial and Accounting Officer)
Dated: November 6, 2025
Compare NTRA vs Leading Stocks
See how NTRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.